Drug Approval Challenges
The transition from large randomized trials to smaller, unrandomized studies in oncology raises significant challenges for the FDA, particularly regarding the approval of new treatments based on limited patient data. As drug prices soar, the ethical dilemma intensifies for patients who must choose between essential medications and basic living expenses. The complexities of drug pricing and the high costs of development further complicate the landscape, highlighting the urgent need for more affordable treatment options.In this clip
From this podcast
Freakonomics Radio
How to Fix the Incentives in Cancer Research | Freakonomics Radio | Episode 449
Related Questions